Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.46 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TK2 | O00142 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6849984 | 1.00 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL27051202 | 1.00 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL13427508 | 1.00 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL1260569 | 1.00 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL8860350 | 0.98 | SLC6A11 (0.47) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL334143 | 0.94 | SLC6A11 (0.48) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL26415000 | 0.93 | SLC6A11 (0.44) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL8327519 | 0.92 | KIF11 (0.42) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL19437634 | 0.90 | SLC6A11 (0.43) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL20915040 | 0.90 | SLC6A11 (0.43) | SLC6A11SLC6A1KIF11KCNH2TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SHIVALILA CHIKDU SHAKTI (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4522744-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2025-03-19 | — | — | EP | disclosed |
| CN-119452084-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240218442-A1 | METHODS FOR INDEXING SAMPLES AND SEQUENCING MULTIPLE POLYNUCLEOTIDE TEMPLATES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| US-9999866-B2 | Preparation of templates for nucleic acid sequencing | ILLUMINA CAMBRIDGE LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| EP-2749566-B1 | SOLID-PHASE CARRIER FOR AMINATED OLIGONUCLEOTIDE | AIST (JP) | 2018-05-09 | — | — | EP | disclosed |
| US-9822134-B2 | System for delivering therapeutic agents into living cells and cells nuclei | SABAG-RFA LTD. (IL) | 2017-11-21 | — | — | US | disclosed |
| US-9822134-B2 | System for delivering therapeutic agents into living cells and cells nuclei | SABAG-RFA LTD. (IL) | 2017-11-21 | — | — | US | disclosed |
| US-20170145499-A1 | METHODS FOR INDEXING SAMPLES AND SEQUENCING MULTIPLE POLYNUCLEOTIDE TEMPLATES | ILLUMINA CAMBRIDGE LIMITED (US) | 2017-05-25 | — | — | US | disclosed |
| US-20090233802-A1 | Methods for indexing samples and sequencing multiple polynucleotide templates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-17 | — | — | US | disclosed |
| US-20090118128-A1 | Preparation of templates for nucleic acid sequencing | ILLUMINA CAMBRIDGE LIMITED (GB) | 2009-05-07 | — | — | US | disclosed |
| US-20090088327-A1 | Method for sequencing a polynucleotide template | SOLEXA LIMITED (GB) | 2009-04-02 | — | — | US | disclosed |
| WO-2008093098-A2 | METHODS FOR INDEXING SAMPLES AND SEQUENCING MULTIPLE NUCLEOTIDE TEMPLATES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2007010251-A2 | PREPARATION OF TEMPLATES FOR NUCLEIC ACID SEQUENCING | SOLEXA LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| US-5912340-A | FORMING STABLE HYBRID WITH DNA, RNA | EPOCH PHARMACEUTICALS, INC. (US) | 1999-06-15 | — | — | US | disclosed |
| US-5419966-A | Solid support for synthesis of 3'-tailed oligonucleotides | MICROPROBE CORPORATION (US) | 1995-05-30 | — | — | US | disclosed |
| EP-0547142-A4 | — | MICROPROBE CORP (US) | 1995-01-18 | — | — | EP | disclosed |
| EP-0547142-A1 | SOLID SUPPORT SYNTHESIS OF 3'-TAILED OLIGONUCLEOTIDES VIA A LINKING MOLECULE | EPOCH PHARMACEUTICALS, INC. (US) | 1993-06-23 | — | — | EP | disclosed |
| WO-1992003464-A1 | SOLID SUPPORT SYNTHESIS OF 3'-TAILED OLIGONUCLEOTIDES VIA A LINKING MOLECULE | MICROPROBE CORPORATION (US) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | ADAR, NSUN2, RNGTT | SLC6A11 4777/4885SLC6A1 4770/4885KIF11 3613/4885 |
| US-20090118128-A1 | Preparation of templates for nucleic acid sequencing | RNGTT, POLRMT, POLM | SLC6A11 4807/4885SLC6A1 4778/4885KIF11 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.